Article
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.
British journal of haematology - 1 Jan 2014
Hexner Elizabeth, Roboz Gail, Hoffman Ron, Luger Selina, Mascarenhas John, Carroll Martin, Clementi Regina, Bensen-Kennedy Debra, Moliterno Alison
Abstract excerpt
JAK2-V617F is central to the pathogenesis of myeloproliferative neoplasms. We examined whether lestaurtinib decreased JAK2-V617F allele burden and evaluated its clinical benefits and tolerability in patients with polycythaemia vera (PV) and essential thrombocythaemia (ET). This phase 2, open-label, multicentre study was designed to detect ≥15% reduction in JAK2-V617F allele burden in 15% of patients. Eligible...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.